Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$391.54M |
$7.61
-10.95%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Company operates oncology-focused biotechnology with immunotherapy assets.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
iTeos Therapeutics is a biotech company focused on oncology, developing cancer immunotherapies.
|
$388.48M |
$10.15
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$388.21M |
$1.70
+3.03%
|
|
GNE
Genie Energy Ltd.
Health Insurance: Captive insurance subsidiary offering tailored health insurance products to retail customers.
|
$388.08M |
$14.57
-0.88%
|
|
BLDE
Blade Air Mobility, Inc.
Blade's Medical segment provides healthcare logistics services including organ transport and related operations.
|
$383.21M |
$4.73
|
|
AHG
Akso Health Group
Sale of medical devices and biometrics hardware.
|
$381.12M |
$1.54
+0.65%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR is pursuing oncology-focused assets (MNPR-101 radiopharmaceuticals) and monoclonal antibody–based therapies, aligning with Biotech - Oncology.
|
$380.87M |
$56.59
-8.33%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$374.21M |
$4.24
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$370.02M |
$7.32
+0.48%
|
|
SOPH
SOPHiA GENETICS S.A.
Liquid Biopsy: MSK-ACCESS application and liquid biopsy analytics integrated into the platform.
|
$368.31M |
$5.46
+5.81%
|
|
AUTL
Autolus Therapeutics plc
Core product: obe-cel CAR-T cell therapy (cell therapy) for rr B-ALL.
|
$367.28M |
$1.37
-4.86%
|
|
DCTH
Delcath Systems, Inc.
Delcath's core offering is a Drug Delivery Platform enabling hepatic delivery of chemotherapy (PHx/HEPZATO KIT) for liver-directed treatment.
|
$362.76M |
$10.37
+1.52%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$361.67M |
$1.63
+1.24%
|
|
AKBA
Akebia Therapeutics, Inc.
Vafseo (vadadustat) is Akebia's core product, an oral small-molecule therapeutic (HIF-PHI) for CKD anemia, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$360.60M |
$1.36
+1.49%
|
|
DDD
3D Systems Corporation
Offers dental equipment and dental 3D printing solutions (NextDent).
|
$353.98M |
$2.76
+4.55%
|
|
ACIU
AC Immune S.A.
Alzheimer's Disease Therapeutics – the company focuses on active immunotherapies and diagnostic assets for Alzheimer's disease.
|
$353.22M |
$3.51
-3.31%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$352.60M |
$7.53
-1.12%
|
|
TECX
Tectonic Therapeutic, Inc.
TX45 is a recombinant fusion protein (Fc-relaxin) developed using TECX's GEODe platform, fitting the Recombinant Proteins & Enzymes category.
|
$351.79M |
$18.86
-3.36%
|
|
KYTX
Kyverna Therapeutics, Inc.
KYTX's lead and pipeline CAR-T products (KYV-101, KYV-102, KYV-201) are autologous/allogeneic CD19 CAR-T cell therapies, a direct cell therapy product category.
|
$351.59M |
$7.80
-4.06%
|
|
BNR
Burning Rock Biotech Limited
Burning Rock's brPROPHET MRD and MCED products are ctDNA-based diagnostics delivered as a liquid biopsy test.
|
$344.69M |
$32.26
-3.18%
|
|
QTRX
Quanterix Corporation
Quanterix directly manufactures and sells ultra-sensitive diagnostic instruments (Simoa platforms) used for biomarker detection in blood and other samples.
|
$343.85M |
$7.39
-7.04%
|
|
AUNA
Auna S.A.
AUNA operates hospitals and provides inpatient and outpatient care, i.e., hospital services.
|
$342.48M |
$4.62
+0.65%
|
Showing page 19 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
